title: Cabozantinib in prostate cancer: the beginning of a precision paradigm?
authors.forename: Susan
authors.initials: S
authors.lastname: Goodin
authors.forename: Robert S
authors.initials: RS
authors.lastname: DiPaola
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D011725:Pyridines; C558660:cabozantinib; D020794:Receptor Protein-Tyrosine Kinases